यूरोपीय संघ - स्वीडिश - EMA (European Medicines Agency)

sanofi winthrop industrie - klopidogrelvätesulfat - stroke; peripheral vascular diseases; atrial fibrillation; myocardial infarction; acute coronary syndrome - antitrombotiska medel - secondary prevention of atherothrombotic eventsclopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-st-segment-elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);st-segment-elevation acute myocardial infarction, in combination with asa in patients undergoing percutaneous coronary intervention (including patients undergoing a stent replacement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy. in patients with moderate to high-risk transient ischemic attack (tia) or minor ischemic stroke (is)clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event. förebyggande av atherothrombotic och tromboemboliska händelser i samband med fibrillationin vuxna patienter med förmaksflimmer som har minst en riskfaktor för vaskulära händelser, är inte lämpliga för behandling med vitamin-k-antagonister och som har låg risk för blödning, clopidogrel är indicerat i kombination med asa för förebyggande av atherothrombotic och tromboemboliska händelser, inklusive stroke.

यूरोपीय संघ - स्वीडिश - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastiska medel - vegzelma in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. vegzelma in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. för vidare information om human epidermal growth factor receptor 2 (her2) status, se avsnitt 5. vegzelma in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with vegzelma in combination with capecitabine. för ytterligare information om her2-status, se avsnitt 5. vegzelma, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (nsclc) other than predominantly squamous cell histology. vegzelma, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent nsclc with epidermal growth factor receptor (egfr) activating mutations (see section 5. vegzelma, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. vegzelma, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. vegzelma, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (vegf) inhibitors or vegf receptor–targeted agents. vegzelma in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. vegzelma, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

स्वीडन - स्वीडिश - Läkemedelsverket (Medical Products Agency)

alk-abelló a/s - allergen, bigift - injektionsvätska, suspension - 100 000 sq-e/ml - allergen, bigift 100000 sq-u aktiv substans; aluminiumoxid, hydratiserad 4 mg adjuvans - insekter

स्वीडन - स्वीडिश - Läkemedelsverket (Medical Products Agency)

alk-abelló a/s - allergen, bigift - injektionsvätska, suspension - styrkeserie - allergen, bigift 1000 sq-u aktiv substans; aluminiumoxid, hydratiserad 4 mikrog adjuvans; allergen, bigift 100 sq-u aktiv substans; aluminiumoxid, hydratiserad 0,04 mg adjuvans; aluminiumoxid, hydratiserad 4 mg adjuvans; allergen, bigift 10000 sq-u aktiv substans; aluminiumoxid, hydratiserad 0,4 mg adjuvans; allergen, bigift 100000 sq-u aktiv substans - insekter

स्वीडन - स्वीडिश - Läkemedelsverket (Medical Products Agency)

alk-abelló a/s - allergen, getinggift - injektionsvätska, suspension - 100 000 sq-e/ml - aluminiumoxid, hydratiserad 4 mg adjuvans; allergen, getinggift 100000 sq-u aktiv substans - insekter

स्वीडन - स्वीडिश - Läkemedelsverket (Medical Products Agency)

alk-abelló a/s - allergen, getinggift - injektionsvätska, suspension - styrkeserie - allergen, getinggift 100000 sq-u aktiv substans; aluminiumoxid, hydratiserad 4 mg adjuvans; aluminiumoxid, hydratiserad 0,4 mg adjuvans; allergen, getinggift 10000 sq-u aktiv substans; aluminiumoxid, hydratiserad 0,04 mg adjuvans; allergen, getinggift 1000 sq-u aktiv substans; aluminiumoxid, hydratiserad 4 mikrog adjuvans; allergen, getinggift 100 sq-u aktiv substans - insekter

यूरोपीय संघ - स्वीडिश - EMA (European Medicines Agency)

bayer ag - aflibercept - wet macular degeneration; macular edema; diabetes complications - ögonsjukdomar - eylea är indicerat för vuxna för behandling av:neovaskulära (våt) åldersrelaterad makuladegeneration (amd);nedsatt syn på grund av makulaödem ödem sekundärt till retinal vein occlusion (branch rvo eller centrala rvo);nedsatt syn på grund av diabetiska makulaödem ödem (dme);synnedsättning på grund av närsynt koroidal kärlnybildning (närsynt cnv).

यूरोपीय संघ - स्वीडिश - EMA (European Medicines Agency)

pharmaswiss ceska republika s.r.o - pegaptanib - wet macular degeneration - ögonsjukdomar - macugen är indicerat för behandling av neovaskulär (våt) åldersrelaterad makuladegenerering (amd).

यूरोपीय संघ - स्वीडिश - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozin propandiolmonohydrat - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - läkemedel som används vid diabetes - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. i tillägg till andra läkemedel för behandling av typ 2-diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 och 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.

यूरोपीय संघ - स्वीडिश - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozin propandiolmonohydrat - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - läkemedel som används vid diabetes - type 2 diabetes mellitusforxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. i tillägg till andra läkemedel för behandling av typ 2-diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 och 5. heart failureforxiga is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseforxiga is indicated in adults for the treatment of chronic kidney disease.